Clinical Trial Update: Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined with VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients with Advanced HER2-Negative Breast Cancer with Brain Metastasis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a PD-L1 monoclonal antibody with VEX metronomic chemotherapy and concurrent or delayed radiotherapy for advanced HER2-negative…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer

Drugs mentioned

• PD-L1 monoclonal antibody
• VEX metronomic chemotherapy

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Brain Metastasis from Advanced HER2-negative Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING